Furthermore, increased expression of LCP1 has been linked to prostate cancer progression.16 LCP1 was shown to be a critical mediator of AP4-dependent prostate cancer progression.17 LCP1 could be an effective therapeutic target for patients with chidamide resistance. This evidence concerns the gene LCP1 and prostate cancer.